Asset profile
Supaglutide
Peptide
Evidence outlook · lead readout
SUPER-1 (NCT04994288) · Type 2 Diabetes
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
SUPER-1 (NCT04994288): In this randomized, double-blind, placebo-controlled Phase 2b/3 trial in 547 adults with type 2 diabetes, once-weekly supaglutide significantly lowered blood-sugar control (HbA1c) at 24 weeks compared with placebo at both tested doses, with the treatment difference clearly outside the range of no effect for each dose.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
110 competitors in this universe: 24 direct rivals (same mechanism and indication), 26 same-class, 60 same-indication; 94 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Supaglutide: this drug | Phase 2/3 | Peptide | GLP-1 receptor | ||
| Dulaglutide (Trulicity) | Approved | Peptide | GLP-1 receptor | ||
| Liraglutide (Saxenda / Victoza) | Approved | Peptide | GLP-1 receptor | ||
| Lixisenatide (Adlyxin / Lyxumia) | Approved | Peptide | GLP-1 receptor | ||
| Orforglipron (Foundayo) | Approved | Small molecule | GLP-1 receptor | ||
| Semaglutide (Wegovy / Ozempic / Rybelsus) | Approved | Peptide | GLP-1 receptor | ||
| Aleniglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Amycretin | Phase 3 | Peptide | GLP-1 receptor, Amylin receptor | ||
| Cagrilintide / Semaglutide (CagriSema) | Phase 3 | Peptide | Amylin receptor, GLP-1 receptor | ||
| CJC-1134-PC | Phase 3 | Peptide | GLP-1 receptor | ||
| Efpeglenatide | Phase 3 | Peptide | GLP-1 receptor | ||
| Elecoglipron | Phase 3 | Small molecule | GLP-1 receptor | ||
| Exendin-4 Fc Fusion (JY09) | Phase 3 | Protein / enzyme therapeutic | GLP-1 receptor | ||
| HDG1901 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HRS-7535 | Phase 3 | Small molecule | GLP-1 receptor | ||
| HSK7653 | Phase 3 | Small molecule | GLP-1 receptor |
…and 95 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
18 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.